ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Budapest, Budapest

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Budapest, Budapest, HUN:

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Budapest, Hungary and 108 other locations

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acu...

Active, not recruiting
Acute Myeloid Leukemia
Drug: S65487 and azacitidine

Phase 1, Phase 2

Servier
Servier

Budapest, Hungary and 10 other locations

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....

Enrolling
Myeloid Leukemia, Philadelphia Positive
Drug: Asciminib Adult formulation group
Drug: Asciminib Pediatric formulation group

Phase 1, Phase 2

Novartis
Novartis

Budapest, Hungary and 38 other locations

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia ...

Active, not recruiting
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

AstraZeneca
AstraZeneca

Budapest, Hungary and 37 other locations

generation (2G) Tyrosine Kinase Inhibitor (TKI) nilotinib (300 mg BID), in adult patients with newly diagnosed Positive Chronic Myelogenous Leukemia...

Active, not recruiting
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Drug: Nilotinib
Drug: Asciminib

Phase 3

Novartis
Novartis

Budapest, Hungary and 119 other locations

Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Budapest, Hungary and 171 other locations

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Budapest, Hungary and 160 other locations

Locations recently updated

clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, ref...

Enrolling
Chronic Myeloid Leukemia
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Drug: ELVN-001

Phase 1

Enliven Therapeutics

Budapest, Hungary and 43 other locations

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling
Leukemia, Lymphocytic, Chronic, B-Cell
Small Lymphocytic Lymphoma
Drug: Venetoclax
Drug: Ibrutinib

Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Budapest, Hungary and 73 other locations

designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Ibrutinib
Drug: Acalabrutinib

Phase 3

Acerta Pharma
Acerta Pharma

Budapest, Hungary and 130 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems